Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company operates in a competitive landscape, with other players in the biopharmaceutical sector also targeting niche markets. On August 10, 2025, Citigroup maintained its "Buy" rating for TVTX, with the stock priced at $16.94. Citigroup also raised its price target for TVTX from $32 to $34, as highlighted by TheFly.
Recently, Travere held its Q2 2025 earnings conference call, featuring key executives like Christopher Cline, Eric M. Dube, and Jula Inrig. The call, which took place on August 6, 2025, likely covered the company's financial performance and strategic initiatives. The stock price of $16.94 reflects a slight increase of 0.18% or $0.03, with fluctuations between $16.55 and $17.34 during the trading day.
Over the past year, TVTX has experienced a high of $25.29 and a low of $8.31, indicating significant volatility. The company's market capitalization is approximately $1.51 billion, reflecting its position in the biopharmaceutical industry. Today's trading volume for TVTX is 1,843,104 shares, suggesting active investor interest.
Citigroup's decision to maintain a "Buy" rating and raise the price target to $34 indicates confidence in Travere's future prospects. The company's focus on rare diseases and recent strategic discussions during the earnings call may contribute to this positive outlook. Investors may find the full transcript of the earnings call on Seeking Alpha for more detailed insights.
